XSTO
ONCO
Market cap33mUSD
Jun 10, Last price
1.51SEK
1D
-0.66%
1Q
-6.21%
IPO
-96.40%
Name
Oncopeptides AB
Chart & Performance
Profile
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 31,648 -10.14% | 35,220 321.54% | 8,355 -92.94% | |||||||
Cost of revenue | 321,131 | 294,348 | 359,858 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (289,483) | (259,128) | (351,503) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 398 | 664 | 271 | |||||||
Tax Rate | ||||||||||
NOPAT | (289,881) | (259,792) | (351,774) | |||||||
Net income | (284,607) 14.25% | (249,111) -26.29% | (337,951) -76.37% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (24) | 407,944 | ||||||||
BB yield | 0.00% | -40.79% | ||||||||
Debt | ||||||||||
Debt current | 5,999 | |||||||||
Long-term debt | 121,894 | 145,825 | 13,085 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 16,658 | 10,509 | 1,815 | |||||||
Net debt | (56,642) | (27,614) | (326,282) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (260,570) | (279,493) | (420,509) | |||||||
CAPEX | (116) | (2,507) | ||||||||
Cash from investing activities | 496 | (116) | (2,507) | |||||||
Cash from financing activities | 263,814 | 106,889 | 392,402 | |||||||
FCF | (282,366) | (273,980) | (347,468) | |||||||
Balance | ||||||||||
Cash | 178,536 | 173,439 | 344,515 | |||||||
Long term investments | 851 | |||||||||
Excess cash | 176,954 | 171,678 | 344,948 | |||||||
Stockholders' equity | (5,355,476) | (5,105,935) | ||||||||
Invested Capital | 192,837 | 5,548,921 | 5,404,807 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 166,437 | 126,836 | 82,320 | |||||||
Price | 1.56 -79.63% | 7.66 -36.95% | 12.15 44.64% | |||||||
Market cap | 259,641 -73.28% | 971,561 -2.86% | 1,000,188 58.14% | |||||||
EV | 202,999 | 943,947 | 676,203 | |||||||
EBITDA | (289,483) | (248,088) | (334,342) | |||||||
EV/EBITDA | ||||||||||
Interest | 5,785 | 883 | ||||||||
Interest/NOPBT |